“…Certainly, support for this suggestion may be provided by a number of other instances in which resistance to the former drug has been accompanied by a reduced therapeutic efficacy of the latter (Pomroy and Whelan, 1993;Leathwick, 1995;Watson et al, 1996;Bridi et al, 1997;Sutherland et al, 1999) and by the results of the present study where moxidectin, despite maintaining an apparently high therapeutic efficacy, was found to exhibit a reduction in its prophylactic activity. This latter result may not be altogether surprising since, in the case of persistent anthelmintics, resistance may be expressed either as a diminished ability to remove worms present at the time of treatment or as a reduction in residual efficacy (Rolfe et al, 1990). Indeed, it is reasonable to expect that, for persistent anthelmintics such as moxidectin, a loss or reduction in prophylactic activity is likely to be the first expression of resistance to them (Rolfe and Fitzgibbon, 1996).…”